Related references
Note: Only part of the references are listed.Direct production of functional matrix metalloproteinase-14 without refolding or activation and its application for in vitro inhibition assays
Dong Hyun Nam et al.
BIOTECHNOLOGY AND BIOENGINEERING (2016)
Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis
W. J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
SAbPred: a structure-based antibody prediction server
James Dunbar et al.
NUCLEIC ACIDS RESEARCH (2016)
Rational Design of Antibody Protease Inhibitors
Tao Liu et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2015)
Blockade of MMP14 Activity in Murine Breast Carcinomas: Implications for Macrophages, Vessels, and Radiotherapy
Eleanor I. Ager et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Blockade of MMP14 Activity in Murine Breast Carcinomas: Implications for Macrophages, Vessels, and Radiotherapy
Eleanor I. Ager et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas
Jillian Cathcart et al.
GENES & DISEASES (2015)
Analysis of heavy and light chain sequences of conventional camelid antibodies from Camelus dromedarius and Camelus bactrianus species
Laura M. Griffin et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2014)
A general protocol for the generation of Nanobodies for structural biology
Els Pardon et al.
NATURE PROTOCOLS (2014)
Is there new hope for therapeutic matrix metalloproteinase inhibition?
Roosmarijn E. Vandenbroucke et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Functional Antibody CDR3 Fusion Proteins with Enhanced Pharmacological Properties
Yong Zhang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2013)
Development of a Periplasmic FRET Screening Method for Protease Inhibitory Antibodies
Dong Hyun Nam et al.
BIOTECHNOLOGY AND BIOENGINEERING (2013)
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens
Jiping Zhang et al.
FASEB JOURNAL (2013)
CDR-H3 Diversity Is Not Required for Antigen Recognition by Synthetic Antibodies
Helena Persson et al.
JOURNAL OF MOLECULAR BIOLOGY (2013)
Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains
Karl R. Schmitz et al.
STRUCTURE (2013)
A monoclonal antibody interferes with TIMP-2 binding and incapacitates the MMP-2-activating function of multifunctional, pro-tumorigenic MMP-14/MT1-MMP
S. A. Shiryaev et al.
ONCOGENESIS (2013)
Development of a Neutralizing Antibody Specific for the Active Form of Matrix Metalloproteinase-13
Shoichi Naito et al.
BIOCHEMISTRY (2012)
A Reverse Binding Motif That Contributes to Specific Protease Inhibition by Antibodies
Eric L. Schneider et al.
JOURNAL OF MOLECULAR BIOLOGY (2012)
Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential
Nett A. Sela-Passwell et al.
NATURE MEDICINE (2012)
New approaches for dissecting protease functions to improve probe development and drug discovery
Edgar Deu et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2012)
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
Chrisostomi Gialeli et al.
FEBS JOURNAL (2011)
Matrix metalloproteinases: protective roles in cancer
Julie Decock et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2011)
Therapeutic potential of matrix metalloprotease inhibitors in neuropathic pain
Rishabh Dev et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Emerging principles in protease-based drug discovery
Marcin Drag et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy Ready for prime time?
Stanley Zucker et al.
CANCER BIOLOGY & THERAPY (2009)
Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis
Laetitia Devy et al.
CANCER RESEARCH (2009)
Matrix metalloproteinase proteomics: substrates, targets, and therapy
Charlotte J. Morrison et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Increased Matrix Metalloproteinase-9 Predicts Poor Wound Healing in Diabetic Foot Ulcers
Yu Liu et al.
DIABETES CARE (2009)
Unraveling the Allosteric Mechanism of Serine Protease Inhibition by an Antibody
Rajkumar Ganesan et al.
STRUCTURE (2009)
Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain
Yasuhiko Kawasaki et al.
NATURE MEDICINE (2008)
Structural insight into distinct mechanisms of protease inhibition by antibodies
Yan Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1)
Christopher J. Farady et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases
Jialiang Hu et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Membrane type-1 matrix metalloproteinase confers aneuploidy and tumorigenicity on mammary epithelial cells
Vladislav S. Golubkov et al.
CANCER RESEARCH (2006)
Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies
E De Genst et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Tumour microenvironment - Opinion - Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
CM Overall et al.
NATURE REVIEWS CANCER (2006)
MT1-MMP:: Universal or particular player in angiogenesis?
L Genís et al.
CANCER AND METASTASIS REVIEWS (2006)
Antibody repertoire development in camelids
E De Genst et al.
DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY (2006)
Targeting proteases: successes, failures and future prospects
Boris Turk
NATURE REVIEWS DRUG DISCOVERY (2006)
The paradox of matrix metalloproteinases in infectious disease
PTG Elkington et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
Selecting and screening recombinant antibody libraries
HR Hoogenboom
NATURE BIOTECHNOLOGY (2005)
Strategies for MMP inhibition in cancer:: Innovations for the post-trial era
CM Overall et al.
NATURE REVIEWS CANCER (2002)
Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire
VK Nguyen et al.
EMBO JOURNAL (2000)
Share Paper
